Imunon Announces 15% Stock Dividend Approval

Imunon ( (IMNN) ) just unveiled an announcement.

On July 28, 2025, IMUNON, Inc. announced a 15% stock dividend approved by its Board of Directors, reflecting the company’s confidence in its clinical programs and long-term growth strategy. This dividend, payable on August 21, 2025, aligns with IMUNON’s commitment to shareholder value and underscores its dedication to advancing its pipeline of therapies, including its lead program in advanced ovarian cancer, currently in Phase 3 trials.

The most recent analyst rating on (IMNN) stock is a Buy with a $210.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.

Spark’s Take on IMNN Stock

According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.

Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.

To see Spark’s full report on IMNN stock, click here.

More about Imunon

IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body’s natural mechanisms to generate effective responses across various human diseases. The company is advancing its non-viral DNA technology through two modalities: TheraPlas for gene-based delivery of therapeutic proteins in solid tumors, and PlaCCine for gene delivery of viral antigens to elicit strong immunological responses.

Average Trading Volume: 856,158

Technical Sentiment Signal: Sell

Current Market Cap: $14.7M

Find detailed analytics on IMNN stock on TipRanks’ Stock Analysis page.